Try our Advanced Search for more refined results

$12.5M Class Deal Reached In Ionis-Akcea Drug Licensing Suit

By Katryna Perera (July 6, 2022, 8:43 PM EDT) -- A class of Akcea Therapeutics Inc. stockholders told Delaware Chancery Court on Tuesday that they had reached a $12.5 million settlement with former directors and officers of the company over claims that an Ionis Pharmaceuticals deal to buy the balance of Akcea stock failed to include the value of derivative claims that Akcea, which is controlled by Ionis, paid too much to license a troubled Ionis developmental drug....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!